AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs

AbbVie Inc. (ABBV) reported fourth-quarter 2024 adjusted earnings of $2.16 per share, which beat the Zacks Consensus Estimate of$2.13. The reported earnings also exceeded the company’s guidance of $2.06-$2.10 issued earlier this month. Earnings declined around 23% year over year due to increased IPR&D expenses incurred during the quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.ABBV’s revenues of $15.10 billion beat the Zacks Consensus Estimate of$14.87 billion. Sales rose 5.6% ...